Table 6 AE type and outcomes for AEs grade 5 (fatal)
From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
Age | Sex | Gene | Indication for treatment | Pulmonary AVMs | Treatment response | Treatment duration at event | Fatal event (SOC) | Drug-related AE? | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Bleeding | Support | Mean Hemoglobin (Hb) | |||||||||
BZB | 67 | Male | ENG | Refractory GI bleeding | Regular blood transfusions | < 6 g/dL | Previously treated, no follow up for 5 ys | Excellent, mean Hb > 10 g/dL | 65 months | Haemoptysis from ruptured PAVM (Vasc Disord) | Possibly related ; theoretical alternate cause: spontaneous rupture |
TH | 69 | Male | ACVRL1 | Refractory epistaxis | Regular blood transfusions | < 7 g/dL | no | Good: mean Hb > 9 g/dL; fewer tx | 10 months | Cardiac failure (Card Disord) | Possibly related; theoretical alternate cause: ischemic cardiopathy |
62 | Male | ENG | Refractory GI bleeding | Regular blood transfusions | < 7 g/dL | no | Partial, mean Hb > 8 g/dL; fewer tx | 23 months | Ischemic stroke (Vasc Disord) | possibly related; theoretical alternate cause: atherosclerosis | |
78 | Male | ENG | Refractory epistaxis | Regular blood transfusions | < 7 g/dL | no | Good: mean Hb > 9 g/dL; fewer tx | 2 months | Catastrophic epistaxis (Resp Disord) | possibly related; theoretical alternate cause: spontaneous nosebleed | |